Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs

To promote optimal and equitable health in women and infants through public health surveillance, research, leadership, and partnership to move science to practice. In carrying out this mission, the Division of Reproductive Health: 1) Enhances the ab

To promote optimal and equitable health in women and infants through public health surveillance, research, leadership, and partnership to move science to practice.

Reference posted NOFOs available on Grants.gov

Official State and Territorial public health agencies. City of New York public health agency and District of Columbia. Applications may be submitted by public and private nonprofit and for-profit organizations and by governments and their agencies; that is, universities, colleges, research institutions, hospitals, other public and private nonprofit and for-profit organizations, State and local governments or their bona fide agents, including the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau, federally recognized Indian tribal governments, Indian tribes, or Indian tribal organizations, and small, minority, women-owned businesses.

PRAMS: The Pregnancy Risk Assessment Monitoring System, is a surveillance project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS collects state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. SID/SUID (Sudden infant Death/Sudden Unexplained Infant Death): The SUID Case Registry aims to generate public health surveillance information about SUID at the national, state, and local levels that is more detailed than what is currently available. Instead of creating an entirely new system, the SUID Case Registry enhances the National Center for Child Death Review program and their Case Reporting System. Validation of Prenatal Substance Use Screening Tools: The purpose of this research is to validate and compare the performance of the most promising substance abuse screening tools that are already available in the literature (for example, the 4Ps-plus, the 5Ps, the Substance Use Risk Profile - Pregnancy Scale (SURP-P), the CRAFFT, the NIDA Quick Screen) and can be used among pregnant women seeking medical services (e.g. antenatal or delivery care) in clinical settings in the United States. Medicaid Expansion and Reproductive Health Care for Women: The intent is to study the use of medical services and health outcomes among low-income women of reproductive age (15-44 years), before and after expansion of Medicaid eligibility. This research will require linkage of state Medicaid data with other key maternal and child health datasets including, but not limited to, birth certificates, death certificates, and hospital discharge data. Perinatal Quality Collaboratives: will support states to enhance the capabilities of state-based perinatal quality collaboratives to improve the quality of perinatal care in their states, including but not limited to: reducing early elective deliveries, increasing use and documentation of use of antenatal steroids, increasing breastfeeding rates, and reducing central line-associated blood stream infections in neonates. Maternal and Child Health Capacity Building:The program promotes and improves the health and well-being of women, children, and families by building capacity at state, local, and tribal levels and to use and apply sound epidemiologic research and scientific information to maternal and child health programs and policies through collaborations with partners. Special Interest Project (SIP)/Progestin contraception and HIV risk: Clinical and laboratory follow-up of a cohort of HIV-infected and uninfected women: The purpose of this SIP is to establish a cohort of HIV-infected and HIV-uninfected women on different types of progestin-containing contraception to assess differences in women's continuation with a given method and the effects of long-term progestin use on markers of HIV risk and efficacy of ART. Also the project will support laboratory studies to analyze the effects of progestin on HIV shedding, inflammatory/immune markers in the genital tract, and the interaction of progestin with antiretroviral therapy on contraceptive and ART efficacy. Objectives in the topic area of Family Planning and HIV Prevention intend to Increase the proportion of pregnancies that are intended; increase the proportion of sexually experienced persons who received reproductive health services; reduce pregnancy rates among adolescent females; and reduce the rate of HIV transmission among adolescents and adults. Teen Pregnancy Prevention: The program is supporting public and private entities to fund medically accurate and age appropriate evidence-based or innovative program models to reduce teen pregnancy. The purpose of the program is to reduce teen pregnancy by working directly with publicly funded clinics to increase access to and use of reproductive health services among vulnerable youth. Activities include building the capacity of staff and clinical providers, establishing partnerships with youth-serving systems, and developing communication efforts. The primary target population is 15- to 19-year-olds, the age group among whom the majority of teen births occur; however, since the Society of Adolescent Health and Medicine and the United Nations Family Planning Association define adolescents as 15-24, the target age group may be expanded. Development and Testing of a Clinic-Based Intervention to Increase Dual Protection against Unintended Pregnancy and STDs among High Risk Female Teens: The purpose of this funding opportunity is to develop and evaluate a clinic-based intervention addressing access to, motivation for, and adherence to dual protection strategies that concurrently protect against unintended pregnancies and sexually transmitted diseases (STDs), including human immunodeficiency virus (HIV) among high risk 15-19 year old females.

Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient.

Applications will be evaluated on the review criteria described in the Notice of Funding Opportunity Announcements (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC.

After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any.

Check Grants.gov for any relevant NOFO information regarding processes for applying for assistance.

After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any.

Cooperative agreement period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.